Androgen deprivation therapy and hormonal status in men with COVID-19
https://doi.org/10.21886/2308-6424-2022-10-4-141-154
Abstract
Severe course of COVID-19 among men compared to the female led to a detailed study of the hormonal status of men with COVID-19. The earliest works about this focused on the incidence and severity of COVID-19 depending on the intake of androgen deprivation therapy. At the same time, different classes of androgen deprivation therapy have different effects on androgen concentration that was not always considered in the analysis. In this regard, we conducted a review of the available literature data with a targeted study of works that included androgen deprivation therapy with a unidirectional effect on the concentration of male sex hormones. In addition, we conducted a review of studies focused on the relationship between COVID-19 and androgens (testosterone and dihydrotestosterone).
About the Authors
A. A. Kamalov
Lomonosov Moscow State University (Lomonosov University)
Russian Federation
Competing Interests:
Russian Federation
Armais A. Kamalov — M.D., Dr.Sc.(Med), Full Prof., Academician of the Russian Academy of Sciences, Head, Dept. of Urology and Andrology, Faculty of Fundamental Medicine, Lomonosov Moscow State University; Headmaster, Medical Research and Educational Centre, Lomonosov Moscow State University.
1 Leninskie Hls., Moscow, 119991
Competing Interests:
The authors declare no conflict of interest
D. A. Ohobotov
Lomonosov Moscow State University (Lomonosov University)
Russian Federation
Competing Interests:
Russian Federation
Dmitry A. Ohobotov — M.D. Cand.Sc.(Med), Assoc.Prof. (Docent), Dept. of Urology and Andrology, Faculty of Fundamental Medicine, Lomonosov Moscow State University; Urologist, Medical Research and Education Center, Lomonosov Moscow State University.
1 Leninskie Hls., Moscow, 119991
Competing Interests:
The authors declare no conflict of interest
O. Yu. Nesterova
Lomonosov Moscow State University (Lomonosov University)
Russian Federation
Competing Interests:
Russian Federation
Olga Yu. Nesterova — Resident, Dept. of Urology and Andrology, Faculty of Fundamental Medicine, Lomonosov Moscow State University.
1 Leninskie Hls., Moscow, 119991
Competing Interests:
The authors declare no conflict of interest
A. A. Strigunov
Lomonosov Moscow State University (Lomonosov University)
Russian Federation
Competing Interests:
Russian Federation
Andrey A. Strigunov — M.D., Postgrad. student, Dept. of Urology and Andrology, Faculty of Fundamental Medicine, Lomonosov Moscow State University.
1 Leninskie Hls., Moscow, 119991
Competing Interests:
The authors declare no conflict of interest
A. S. Tivtikyan
Lomonosov Moscow State University (Lomonosov University)
Russian Federation
Competing Interests:
Russian Federation
Alexander S. Tivtikyan — M.D., Urologist, Medical Research and Education Center, Lomonosov Moscow State University.
1 Leninskie Hls., Moscow, 119991
Competing Interests:
The authors declare no conflict of interest
References
1. Hamdi S, Bendayan M, Huyghe E, Soufir JC, Amar E, El Osta R, Plotton I, Delalande C, Perrin J, Leroy C, Bouker A, Pons H, Lejeune H, Robin G, Boitrelle F. COVID-19 and andrology: Recommendations of the French-speaking society of andrology (Société d'Andrologie de langue Française SALF). Basic Clin Androl. 2020;30:10. https://doi.org/10.1186/s12610-020-00106-4
2. Hoffmann M, Kleine-Weber H, Schroeder S, Krüger N, Herrler T, Erichsen S, Schiergens TS, Herrler G, Wu NH, Nitsche A, Müller MA, Drosten C, Pöhlmann S. SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor. Cell. 2020;181(2):271-280.e8. https://doi.org/10.1016/j.cell.2020.02.052
3. Lucas JM, Heinlein C, Kim T, Hernandez SA, Malik MS, True LD, Morrissey C, Corey E, Montgomery B, Mostaghel E, Clegg N, Coleman I, Brown CM, Schneider EL, Craik C, Simon JA, Bedalov A, Nelson PS. The androgen-regulated protease TMPRSS2 activates a proteolytic cascade involving components of the tumor microenvironment and promotes prostate cancer metastasis. Cancer Discov. 2014;4(11):1310-25. https://doi.org/10.1158/2159-8290.CD-13-1010
4. Rozhivanov R.V., Andreeva E.N., Melnichenko G.A., Mokrysheva N.G. Androgens and Antiandrogens influence on COVID-19 disease in men. Problems of Endocrinology. 2020;66(4):77-81. (In Russ.) https://doi.org/10.14341/probl12500
5. Lieberman R. Androgen deprivation therapy for prostate cancer chemoprevention: current status and future directions for agent development. Urology. 2001;58(2 Suppl 1):83-90. https://doi.org/10.1016/s0090-4295(01)01247-x
6. Montopoli M, Zumerle S, Vettor R, Rugge M, Zorzi M, Catapano CV, Carbone GM, Cavalli A, Pagano F, Ragazzi E, Prayer-Galetti T, Alimonti A. Androgen-deprivation therapies for prostate cancer and risk of infection by SARS-CoV-2: a population-based study (N = 4532). Ann Oncol. 2020;31(8):1040-1045. https://doi.org/10.1016/j.annonc.2020.04.479
7. Gheiler EL, Tiguert R. Current concepts in androgen deprivation therapy--is there a "best" endocrine treatment? World J Urol. 2000;18(3):190-3. https://doi.org/10.1007/s003459900099
8. Mishugin S.V., Gritskevich A.A., Rusakov I.G. Development and clinical effectiveness of antiandrogens in the treatment of advanced prostate cancer. Medical Council. 2016;(10):34-37. (In Russ.) https://doi.org/10.21518/2079-701X-2016-10-34-37
9. Markova A.S., Matveev V.B. Androgen deprivation therapy with luteinizing hormone-releasing hormone antagonists for prostate cancer: best disease control with a lower risk of side effects. results of analysis of 6 comparative randomized phase III trials of degarelix and luteinizin. Cancer Urology. 2014;10(1):76-81. (In Russ.) https://doi.org/10.17650/1726-9776-2014-10-1-76-81
10. Barash Y., Maximov S., Bershtein L., Gershfeld E., Danilova M. Gonadotropin-releasing hormone agonists in endometrial pathology. Journal of obstetrics and women's diseases. 2008;57(4):64-72. (In Russ.) EDN: KUGRDD
11. Welén K, Överby AK, Ahlm C, Freyhult E, Robinsson D, Henningsson AJ, Stranne J, Bremell D, Angelin M, Lindquist E, Buckland R, Carlsson CT, Pauksens K, Bill-Axelsson A, Akre O, Ryden C, Wagenius M, Bjartell A, Nilsson AC, Styrke J, Repo J, Balkhed ÅÖ, Niward K, Gisslén M, Josefsson A. COVIDENZA - A prospective, multicenter, randomized PHASE II clinical trial of enzalutamide treatment to decrease the morbidity in patients with Corona virus disease 2019 (COVID-19): a structured summary of a study protocol for a randomised controlled trial. Trials. 2021;22(1):209. https://doi.org/10.1186/s13063-021-05137-4
12. Koskinen M, Carpen O, Honkanen V, Seppänen MRJ, Miettinen PJ, Tuominen JA, Raivio T. Androgen deprivation and SARS-CoV-2 in men with prostate cancer. Ann Oncol. 2020;31(10):1417-1418. https://doi.org/10.1016/j.annonc.2020.06.015
13. Caffo O, Zagonel V, Baldessari C, Berruti A, Bortolus R, Buti S, Ceresoli GL, Donini M, Ermacora P, Fornarini G, Fratino L, Masini C, Massari F, Mosca A, Mucciarini C, Procopio G, Tucci M, Verri E, Zucali P, Buttigliero C. On the relationship between androgen-deprivation therapy for prostate cancer and risk of infection by SARS-CoV-2. Ann Oncol. 2020;31(10):1415-1416. https://doi.org/10.1016/j.annonc.2020.06.005
14. Patel VG, Zhong X, Liaw B, Tremblay D, Tsao CK, Galsky MD, Oh WK. Does androgen deprivation therapy protect against severe complications from COVID-19? Ann Oncol. 2020;31(10):1419-1420. https://doi.org/10.1016/j.annonc.2020.06.023
15. Bennani NN, Bennani-Baiti IM. Androgen deprivation therapy may constitute a more effective COVID-19 prophylactic than therapeutic strategy. Ann Oncol. 2020;31(11):1585-1586. https://doi.org/10.1016/j.annonc.2020.08.2095
16. Gedeborg R, Styrke J, Loeb S, Garmo H, Stattin P. Androgen deprivation therapy and excess mortality in men with prostate cancer during the initial phase of the COVID-19 pandemic. PLoS One. 2021;16(10):e0255966. https://doi.org/10.1371/journal.pone.0255966
17. Cadegiani FA, McCoy J, Gustavo Wambier C, Vaño-Galván S, Shapiro J, Tosti A, Zimerman RA, Goren A. Proxalutamide Significantly Accelerates Viral Clearance and Reduces Time to Clinical Remission in Patients with Mild to Moderate COVID-19: Results from a Randomized, Double-Blinded, Placebo-Controlled Trial. Cureus. 2021;13(2):e13492. https://doi.org/10.7759/cureus.13492
18. Welén K, Rosendal E, Gisslén M, Lenman A, Freyhult E, Fonseca-Rodríguez O, Bremell D, Stranne J, Balkhed ÅÖ, Niward K, Repo J, Robinsson D, Henningsson AJ, Styrke J, Angelin M, Lindquist E, Allard A, Becker M, Rudolfsson S, Buckland R, Carlsson CT, Bjartell A, Nilsson AC, Ahlm C, Connolly AF, Överby AK, Josefsson A. A Phase 2 Trial of the Effect of Antiandrogen Therapy on COVID-19 Outcome: No Evidence of Benefit, Supported by Epidemiology and In Vitro Data. Eur Urol. 2022;81(3):285-293. https://doi.org/10.1016/j.eururo.2021.12.013
19. Lee KM, Heberer K, Gao A, Becker DJ, Loeb S, Makarov DV, Gulanski B, DuVall SL, Aslan M, Lee J, Shih MC, Lynch JA, Hauger RL, Rettig M. A Population-Level Analysis of the Protective Effects of Androgen Deprivation Therapy Against COVID-19 Disease Incidence and Severity. Front Med (Lausanne). 2022;9:774773. https://doi.org/10.3389/fmed.2022.774773
20. Xiang Y, Wong KC, So HC. Exploring Drugs and Vaccines Associated with Altered Risks and Severity of COVID-19: A UK Biobank Cohort Study of All ATC Level-4 Drug Categories Reveals Repositioning Opportunities. Pharmaceutics. 2021;13(9):1514. https://doi.org/10.3390/pharmaceutics13091514
21. McCoy J, Cadegiani FA, Wambier CG, Herrera S, Vaño-Galván S, Mesinkovska NA, Ramos PM, Shapiro J, Sinclair R, Tosti A, Goren A. 5-alpha-reductase inhibitors are associated with reduced frequency of COVID-19 symptoms in males with androgenetic alopecia. J Eur Acad Dermatol Venereol. 2021;35(4):e243-e246. Erratum in: J Eur Acad Dermatol Venereol. 2021;35(7):1595. https://doi.org/10.1111/jdv.17021
22. Cadegiani FA, McCoy J, Gustavo Wambier C, Goren A. Early Antiandrogen Therapy With Dutasteride Reduces Viral Shedding, Inflammatory Responses, and Time-to-Remission in Males With COVID-19: A Randomized, Double-Blind, Placebo-Controlled Interventional Trial (EAT-DUTA AndroCoV Trial - Biochemical). Cureus. 2021;13(2):e13047. https://doi.org/10.7759/cureus.13047
23. Sari Motlagh R, Abufaraj M, Karakiewicz PI, Rajwa P, Mori K, Mun DH, Shariat SF. Association between SARS-CoV-2 infection and disease severity among prostate cancer patients on androgen deprivation therapy: a systematic review and meta-analysis. World J Urol. 2022;40(4):907-914. https://doi.org/10.1007/s00345-021-03810-6
24. Wambier CG, Vaño-Galván S, McCoy J, Gomez-Zubiaur A, Herrera S, Hermosa-Gelbard Á, Moreno-Arrones OM, Jiménez-Gómez N, González-Cantero A, Fonda-Pascual P, Segurado-Miravalles G, Shapiro J, Pérez-García B, Goren A. Androgenetic alopecia present in the majority of patients hospitalized with COVID-19: The "Gabrin sign". J Am Acad Dermatol. 2020;83(2):680-682. https://doi.org/10.1016/j.jaad.2020.05.079
25. Lee J, Yousaf A, Fang W, Kolodney MS. Male balding is a major risk factor for severe COVID-19. J Am Acad Dermatol. 2020;83(5):e353-e354. Erratum in: J Am Acad Dermatol. 2021;85(3):799. https://doi.org/10.1016/j.jaad.2020.07.062
26. Müller Ramos P, Ianhez M, Amante Miot H. Alopecia and grey hair are associated with COVID-19 Severity. Exp Dermatol. 2020;29(12):1250-1252. https://doi.org/10.1111/exd.14220
27. Scroppo FI, Costantini E, Zucchi A, Illiano E, Trama F, Brancorsini S, Crocetto F, Gismondo MR, Dehò F, Mercuriali A, Bartoletti R, Gaeta F. COVID-19 disease in clinical setting: impact on gonadal function, transmission risk, and sperm quality in young males. J Basic Clin Physiol Pharmacol. 2021;33(1):97-102. https://doi.org/10.1515/jbcpp-2021-0227
28. Temiz MZ, Dincer MM, Hacibey I, Yazar RO, Celik C, Kucuk SH, Alkurt G, Doganay L, Yuruk E, Muslumanoglu AY. Investigation of SARS-CoV-2 in semen samples and the effects of COVID-19 on male sexual health by using semen analysis and serum male hormone profile: A cross-sectional, pilot study. Andrologia. 2021;53(2):e13912. https://doi.org/10.1111/and.13912
29. Gul A, Zengin S, Dundar G, Ozturk M. Do SARS-CoV-2 Infection (COVID-19) and the Medications Administered for Its Treatment Impair Testicular Functions? Urol Int. 2021;105(11-12):944-948. https://doi.org/10.1159/000517925
30. Enikeev D, Taratkin M, Morozov A, Petov V, Korolev D, Shpikina A, Spivak L, Kharlamova S, Shchedrina I, Mestnikov O, Fiev D, Ganzha T, Geladze M, Mambetova A, Kogan E, Zharkov N, Demyashkin G, Shariat SF, Glybochko P. Prospective two-arm study of the testicular function in patients with COVID-19. Andrology. 2022;10(6):1047-1056. https://doi.org/10.1111/andr.13159
31. Koç E, Keseroğlu BB. Does COVID-19 Worsen the Semen Parameters? Early Results of a Tertiary Healthcare Center. Urol Int. 2021;105(9-10):743-748. https://doi.org/10.1159/000517276
32. Salonia A, Pontillo M, Capogrosso P, Gregori S, Carenzi C, Ferrara AM, Rowe I, Boeri L, Larcher A, Ramirez GA, Tresoldi C, Locatelli M, Cavalli G, Dagna L, Castagna A, Zangrillo A, Tresoldi M, Landoni G, Rovere-Querini P, Ciceri F, Montorsi F. Testosterone in males with COVID-19: A 7-month cohort study. Andrology. 2022;10(1):34-41. https://doi.org/10.1111/andr.13097
33. Ibishev KS, Mamedov EA, Gusova ZR, Palenyy AI, Prokop YO. [Serum testosterone and testicular hemodynamics before and after infection with SARS-COV-2 (pilot study)]. Urologiia. 2021;(5):5-9. (In Russ.) https://doi.org/10.18565/urology.2021.5.5-9
34. Li C, Ye Z, Zhang AJX, Chan JFW, Song W, Liu F, Chen Y, Kwan MYW, Lee ACY, Zhao Y, Wong BHY, Yip CCY, Cai JP, Lung DC, Sridhar S, Jin D, Chu H, To KKW, Yuen KY. Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection by Intranasal or Intratesticular Route Induces Testicular Damage. Clin Infect Dis. 2022;75(1):e974-e990. https://doi.org/10.1093/cid/ciac142
35. Pagano MT, Peruzzu D, Busani L, Pierdominici M, Ruggieri A, Antinori A, D'Offizi G, Petrosillo N, Palmieri F, Piselli P, Cicalini S, Notari S, Nicastri E, Agrati C, Ippolito G, Vaia F, Gagliardi MC, Capobianchi MR, Ortona E; INMI-ISS COVID-19 team. Predicting respiratory failure in patients infected by SARS-CoV-2 by admission sex-specific biomarkers. Biol Sex Differ. 2021;12(1):63. https://doi.org/10.1186/s13293-021-00407-x
36. Zheng S, Zou Q, Zhang D, Yu F, Bao J, Lou B, Xie G, Lin S, Wang R, Chen W, Wang Q, Teng Y, Feng B, Shen Y, Chen Y. Serum level of testosterone predicts disease severity of male COVID-19 patients and is related to T-cell immune modulation by transcriptome analysis. Clin Chim Acta. 2022;524:132-138. https://doi.org/10.1016/j.cca.2021.11.006
37. Vishvakarma VK, Pal S, Singh P, Bahadur I. Interactions between main protease of SARS-CoV-2 and testosterone or progesterone using computational approach. J Mol Struct. 2022;1251:131965. https://doi.org/10.1016/j.molstruc.2021.131965
38. Kumari K, Kumar A, Bahadur I, Singh P. Investigate the interaction of testosterone/progesterone with ionic liquids on varying the anion to combat COVID-19: Density functional theory calculations and molecular docking approach. J Phys Org Chem. 2021;34(12):e4273. https://doi.org/10.1002/poc.4273
39. Loschwitz J, Jäckering A, Keutmann M, Olagunju M, Eberle RJ, Coronado MA, Olubiyi OO, Strodel B. Novel inhibitors of the main protease enzyme of SARS-CoV-2 identified via molecular dynamics simulation-guided in vitro assay. Bioorg Chem. 2021;111:104862. https://doi.org/10.1016/j.bioorg.2021.104862
40. Barbosa LP, da Silva Aguiar S, Santos PA, Dos Santos Rosa T, Maciel LA, de Deus LA, Neves RVP, de Araújo Leite PL, Gutierrez SD, Sousa CV, Korhonen MT, Degens H, Simões HG. Relationship between inflammatory biomarkers and testosterone levels in male master athletes and non-athletes. Exp Gerontol. 2021;151:111407. https://doi.org/10.1016/j.exger.2021.111407
41. Swerdloff RS, Dudley RE, Page ST, Wang C, Salameh WA. Dihydrotestosterone: Biochemistry, Physiology, and Clinical Implications of Elevated Blood Levels. Endocr Rev. 2017;38(3):220-254. https://doi.org/10.1210/er.2016-1067
42. Steward A, Bayley DL. Effects of androgens in models of rheumatoid arthritis. Agents Actions. 1992;35(3-4):268-72. https://doi.org/10.1007/BF01997510
43. Parkar M, Tabona P, Newman H, Olsen I. IL-6 expression by oral fibroblasts is regulated by androgen. Cytokine. 1998 Aug;10(8):613-9. doi: 10.1006/cyto.1998.0336.
44. Gornstein RA, Lapp CA, Bustos-Valdes SM, Zamorano P. Androgens modulate interleukin-6 production by gingival fibroblasts in vitro. J Periodontol. 1999;70(6):604-9. https://doi.org/10.1902/jop.1999.70.6.604
45. Sánchez-García L, Wilkins-Rodriguez A, Salaiza-Suazo N, Morales-Montor J, Becker I. Dihydrotestosterone enhances growth and infectivity of Leishmania Mexicana. Parasite Immunol. 2018;40(3). https://doi.org/10.1111/pim.12512
46. Durrani F, Phelps DS, Weisz J, Silveyra P, Hu S, Mikerov AN, Floros J. Gonadal hormones and oxidative stress interaction differentially affects survival of male and female mice after lung Klebsiella pneumoniae infection. Exp Lung Res. 2012;38(4):165-72. https://doi.org/10.3109/01902148.2011.654045
47. Zhou T, Wu J, Zeng Y, Li J, Yan J, Meng W, Han H, Feng F, He J, Zhao S, Zhou P, Wu Y, Yang Y, Han R, Jin W, Li X, Yang Y, Li X. SARS-CoV-2 triggered oxidative stress and abnormal energy metabolism in gut microbiota. MedComm (2020). 2022;3(1):e112. https://doi.org/10.1002/mco2.112
48. Kumar N, Zuo Y, Yalavarthi S, Hunker KL, Knight JS, Kanthi Y, Obi AT, Ganesh SK. SARS-CoV-2 Spike Protein S1-Mediated Endothelial Injury and Pro-Inflammatory State Is Amplified by Dihydrotestosterone and Prevented by Mineralocorticoid Antagonism. Viruses. 2021;13(11):2209. https://doi.org/10.3390/v13112209
49. Schroeder M, Tuku B, Jarczak D, Nierhaus A, Bai T, Jacobsen H, Zickler M, Mueller Z, Stanelle-Bertram S, Meinhardt A, Aberle J, Kluge S, Gabriel G. The majority of male patients with COVID-19 present low testosterone levels on admission to Intensive Care in Hamburg, Germany: a retrospective cohort study. medRxiv. 2020;05(07):20073817. https://doi.org/10.1101/2020.05.07.20073817
50. Schroeder M, Schaumburg B, Mueller Z, Parplys A, Jarczak D, Roedl K, Nierhaus A, de Heer G, Grensemann J, Schneider B, Stoll F, Bai T, Jacobsen H, Zickler M, Stanelle-Bertram S, Klaetschke K, Renné T, Meinhardt A, Aberle J, Hiller J, Peine S, Kreienbrock L, Klingel K, Kluge S, Gabriel G. High estradiol and low testosterone levels are associated with critical illness in male but not in female COVID-19 patients: a retrospective cohort study. Emerg Microbes Infect. 2021;10(1):1807-1818. https://doi.org/10.1080/22221751.2021.1969869
Review
For citations:
Kamalov A.A., Ohobotov D.A., Nesterova O.Yu., Strigunov A.A., Tivtikyan A.S. Androgen deprivation therapy and hormonal status in men with COVID-19. Urology Herald. 2022;10(4):141-154. (In Russ.) https://doi.org/10.21886/2308-6424-2022-10-4-141-154
Views:
1490
Email this article 
